Cargando…

Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis

Oncogenic mutations in the EGFR gene account for 15–20% of lung adenocarcinoma (LUAD) cases. However, the mechanism for EGFR driven tumor development and growth is not fully understood. Here, using an mRNA expression profiling-based approach we identified betacellulin (BTC) as one the gene upregulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chava, Suresh, Bugide, Suresh, Zhang, Xuchen, Gupta, Romi, Wajapeyee, Narendra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048069/ https://www.ncbi.nlm.nih.gov/pubmed/35494243 http://dx.doi.org/10.1016/j.isci.2022.104211

Ejemplares similares

CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer
por: Bugide, Suresh, et al.
Publicado: (2023)

Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
por: Chava, Suresh, et al.
Publicado: (2021)

PSPH promotes melanoma growth and metastasis by metabolic-deregulation–mediated transcriptional activation of NR4A1
por: Rawat, Vipin, et al.
Publicado: (2021)

Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
por: Chava, Suresh, et al.
Publicado: (2022)

LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
por: Malvi, Parmanand, et al.
Publicado: (2020)

The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis
por: Mason, Lawrence David, et al.
Publicado: (2021)

N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production
por: Malvi, Parmanand, et al.
Publicado: (2021)

UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress
por: Dutta, Roshan, et al.
Publicado: (2022)

HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
por: Malvi, Parmanand, et al.
Publicado: (2023)

LKB1 preserves genome integrity by stimulating BRCA1 expression
por: Gupta, Romi, et al.
Publicado: (2015)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Transcriptional regulators and alterations that drive melanoma initiation and progression
por: Gupta, Romi, et al.
Publicado: (2020)

Identification of the Mutational Landscape of Gynecological Malignancies
por: Chava, Suresh, et al.
Publicado: (2020)

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations
por: Shi, Puyu, et al.
Publicado: (2019)

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R
por: Bugide, Suresh, et al.
Publicado: (2020)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Betacellulin inhibits osteogenic differentiation and stimulates proliferation through HIF-1α
por: Genetos, Damian C., et al.
Publicado: (2010)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
por: Zhang, Shuo, et al.
Publicado: (2021)

Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
por: Malvi, Parmanand, et al.
Publicado: (2022)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth
por: Gupta, Romi, et al.
Publicado: (2016)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Betacellulin Induces Increased Retinal Vascular Permeability in Mice
por: Anand-Apte, Bela, et al.
Publicado: (2010)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
por: Li, Teng, et al.
Publicado: (2021)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
por: Kumarakulasinghe, Nesaretnam Barr, et al.
Publicado: (2016)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2022)

Betacellulin regulates the proliferation and differentiation of retinal progenitor cells in vitro
por: Zhang, Dandan, et al.
Publicado: (2017)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aqaekrkf27o33p44rrm5cv6ess